We have shorts playing their games, meanwhile markets are poised for a 1700 S&P. Exel have been a lagger for more than 2 years. Why? Short Interest had control for the last years, but things are changing in a hurry. As markets shows signs of Global recovery, we may bounce off these levels into a much dseirable position as Exel's pipeline approaches 2014 and other milestones with Big Pharma's. We could be entering a progressive phase of Large Pharma's pocket books before 2014 Completion of Exels most dramatic portofolio. CABO, Comet trials. Get ready for recognition from Large Pharma's. We are in a different phase with Exel. Its just going to be good and get better . Look for Bidders. $'S For Large Pharma's are mow, while Exels are still cheap. Pharma's would rather get a complete pipeline with accessories at $15.00 rather than $50- $100.